Intranasal delivery of a truncated recombinant human SP‐D is effective at down‐regulating allergic hypersensitivity in mice sensitized to allergens of Aspergillus fumigatus

• Published in: Clinical and experimental immunology 2002-10, Vol.130 (1), p.19-24
• Main Authors: STRONG, P., REID, K. B. M., CLARK, H.
• Format: Article
• Language: English
• Subjects: ABPA allergy IL‐12 plethysmography SP‐D; Administration, Intranasal; Allergens - immunology; Allergens - toxicity; Animal Studies; Animals; Antibodies, Fungal - biosynthesis; Antibodies, Fungal - immunology; Antigens, Fungal - immunology; Antigens, Fungal - toxicity; Antigens, Plant; Aspergillosis, Allergic Bronchopulmonary - chemically induced; Aspergillosis, Allergic Bronchopulmonary - drug therapy; Aspergillosis, Allergic Bronchopulmonary - pathology; Aspergillus fumigatus - immunology; Biological and medical sciences; Bronchial Hyperreactivity - chemically induced; Bronchial Hyperreactivity - drug therapy; Drug Evaluation, Preclinical; Eosinophilia - chemically induced; Eosinophilia - drug therapy; Female; Fungal Proteins - immunology; Fungal Proteins - toxicity; Histamine and antagonists. Allergy; Humans; Immunization; Interferon-gamma - analysis; Interleukin-12 - analysis; Interleukin-4 - analysis; Lung - pathology; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Peptide Fragments - administration & dosage; Peptide Fragments - pharmacology; Peptide Fragments - therapeutic use; Pharmacology. Drug treatments; Plethysmography, Whole Body; Pulmonary Surfactant-Associated Protein A - analysis; Pulmonary Surfactant-Associated Protein A - pharmacology; Pulmonary Surfactant-Associated Protein A - therapeutic use; Pulmonary Surfactant-Associated Protein D - administration & dosage; Pulmonary Surfactant-Associated Protein D - analysis; Pulmonary Surfactant-Associated Protein D - chemistry; Pulmonary Surfactant-Associated Protein D - pharmacology; Pulmonary Surfactant-Associated Protein D - therapeutic use; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - pharmacology; Recombinant Fusion Proteins - therapeutic use; Species Specificity; Spleen - chemistry; Spleen - immunology; Spleen - pathology
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1046/j.1365-2249.2002.01968.x

Summary C57BL/6 mice were sensitized to Aspergillus fumigatus 1‐week culture filtrate, which is rich in the non‐glycosylated allergen Asp f1, a major allergen in allergic bronchopulmonary aspergillosis (ABPA). A comparison of the effect of treatment of allergen challenged mice by intranasal administration of a 60‐kDa truncated recombinant form of human SP‐D (rfhSP‐D) or recombinant full length SP‐A (rhSP‐A) was undertaken. Treatment with rfhSP‐D produced significant reduction in IgE, IgG1 and peripheral blood eosinophilia and treatment with rfhSP‐D, but not rhSP‐A resulted in a significant reduction in airway hyperresponsiveness as measured by whole body plethysmography. Lung histology revealed less peribronchial lymphocytic infiltration in mice treated with rfhSP‐D. Intracellular cytokine staining of spleen homogenates showed increases in IL‐12 and IFN‐γ and decrease in IL‐4. The level of endogenous mouse SP‐D was elevated sixfold in the lungs of sensitized mice and was not affected by treatment with rfhSP‐D. Taken with our previous studies, with a BALB/c mouse model of ABPA using a 3‐week A. fumigatus culture filtrate, the present results show that rfhSP‐D can suppress the development of allergic symptoms in sensitized mice independent of genetic background and using a different preparation of A. fumigatus allergens.